Stockscreener 앱 받기
1.06
5.36%
-0.06
시간 외 거래:
1.09
0.03
+2.83%
Heron Therapeutics Inc 주식(HRTX)의 최신 뉴스
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to “Hold” - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to "Hold" - MarketBeat
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Heron Therapeutics Q3 2024 Earnings Preview - MSN
Heron Therapeutics Inc (NASDAQ: HRTX) Declines -1.68%: This $177.95 million Stock Could Go Down -669.23% - Stocks Register
Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 6.0% - MarketBeat
Northland Capmk Has Pessimistic View of HRTX Q4 Earnings - Defense World
Equities Analysts Set Expectations for HRTX Q4 Earnings - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Raised to Buy at StockNews.com - Defense World
Heron Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Needham & Company LLC Has Lowered Expectations for Heron Therapeutics (NASDAQ:HRTX) Stock Price - MarketBeat
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge - Simply Wall St
Heron Therapeutics Inc (HRTX) Quarterly 10-Q Report - Quartzy
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30% - Simply Wall St
Earnings call: Heron Therapeutics projects higher Q4 revenue By Investing.com - Investing.com UK
Heron Therapeutics Reports Q3 2024 Results and Narrows Guidance - TipRanks
Heron Therapeutics: Q3 Earnings Snapshot - CT Insider
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Heron Therapeutics reports Q3 EPS (3c), consensus (3c) - TipRanks
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - PR Newswire
Heron Therapeutics (HRTX) Set to Announce Earnings on Tuesday - Defense World
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Heron Therapeutics (HRTX) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock - Yahoo Finance UK
Heron Therapeutics Strengthens Leadership with New Board Appointment - TipRanks
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - StockTitan
Bunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt - The Globe and Mail
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - Longview News-Journal
SG Americas Securities LLC Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Antinauseants Market Insights, Forecast to 2031Heron - openPR
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update - MarketBeat
Heron Therapeutics Inc (HRTX) deserves deeper analysis - US Post News
Investor’s Toolkit: Key Ratios for Assessing Heron Therapeutics Inc (HRTX)’s Performance - The Dwinnex
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Congress Park Capital LLC - MarketBeat
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids - The Malaysian Reserve
Its Stock Has Paid Off Big Time For Heron Therapeutics Inc - SETE News
AQR Capital Management LLC Raises Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Inc Inc. (HRTX) Price Performance: The Role of Supply and Demand - The InvestChronicle
Can you now get a good deal on Heron Therapeutics Inc’s shares? - US Post News
Squarepoint Ops LLC Purchases 286,160 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Buying Buzz: Heron Therapeutics Inc [HRTX] EVP, Chief Development Officer Forbes William P purchases 25,000 shares of the company – Knox Daily - Knox Daily
HRTX’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
When Can We Expect A Profit From Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Simply Wall St
Get in on Heron Therapeutics Inc’s (HRTX) buy-in window today! - SETE News
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability - Yahoo Finance
0.93%
3.55%
자본화:
|
볼륨(24시간):